S-1 and CPT-11 Plus Ramucirumab (IRIS+Rmab) as Second-Line Chemotherapy for Patients with Oxaliplatin-Refractory Metastatic Colorectal Cancer (mCRC): A Multicenter Phase II Study in Japan (N-DOCC-F-C-1701).
Kobayashi K, Morita M, Fukui S, Ito S, Inoue Y, Yamaguchi I, Mine Y, Kosaka T, Kuba S, Sakimura C, Yamanouchi K, Soyama A, Ono S, Adachi T, Natsuda K, Okada S, Tetsuo H, Ikebe A, Yamaguchi S, Enjoji T, Okada K, Haraguchi M, Taniguchi K, Fujioka H, Kuroki T, Matsuo M, Azuma T, Kamohara Y, Hashimoto T, Moriuchi H, Kitajima T, Kawakami S, Enjoji A, Suto R, Hidaka M, Torashima Y, Hayashida N, Kanetaka K, Takatsuki M, Eguchi S.
Kobayashi K, et al. Among authors: kuba s.
Kurume Med J. 2020 Jul 1;66(1):43-47. doi: 10.2739/kurumemedj.MS661007. Epub 2020 May 1.
Kurume Med J. 2020.
PMID: 32378536
Free article.